ClinicalTrials.gg
CompletedNCT03643965NefigardUpdated Dec 3, 2024Results posted

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

A Phase 3 interventional study of Nefecon and Placebo oral capsule in Primary IgA Nephropathy, sponsored by Calliditas Therapeutics AB. Completed at 142 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Calliditas Therapeutics AB · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
365
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
16th of 67
365 · median 67
Started
2018
with 4 others
Phase 3
21 of 73
8 open now
Registered
20th of 73
by date
Lead sponsor
3 of 73
Calliditas Therapeutics AB

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 16th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 21 in phase 3, and was the 20th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).

Read the detailed description

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of oral Nefecon compared to matching placebo in patients with primary IgAN on a background of optimized RAS inhibitor therapy. The study will consist of 2 parts, Part A and Part B. Part A will include a 9 month blinded Treatment Period, and a 3-month Follow up Period. Part B of the study will consist of a 12-month observational Follow up Period; no study drug will be administered during Part B. Part A and B will be blinded. Safety will be monitored by an independent Data Safety Monitoring Board.

03

Conditions studied

  • Primary IgA Nephropathy

Keywords

  • IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male patients ≥18 years
  2. -verified IgA nephropathy
  3. Stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or Maximum Tolerated Dose (MTD) according to the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines
  4. Urine protein creatinine ratio ≥1 g/24hr
  5. ≥35 mL/min per 1.73 m2 and ≤90 mL/min per 1.73 m2 using the Chronic Kidney Diseae Epidemiology Collaboration (CKD-EPI) formula
  6. Willing and able to give

Exclusion criteria

Exclusion Criteria:

  1. Systemic diseases that may cause mesangial IgA deposition.
  2. Patients who have undergone a kidney transplant.
  3. Patients with acute or chronic infectious disease including hepatitis, tuberculosis, (HIV), and chronic urinary tract infections.
  4. Patients with liver cirrhosis, as assessed by the Investigator.
  5. Patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled.
  6. Patients with history of unstable angina, class III or IV congestive heart failure, and/or arrhythmia, as judged by the Investigator;
  7. Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator
  8. Patients with diagnosed within the past 5 years.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
365 participants (actual)

Study arms

  • Experimental
    Nefecon

    Nefecon 16 mg once daily by mouth for 9 months.

    Drug: Nefecon

  • Placebo comparator
    Placebo oral capsule

    Placebo oral capsule once daily by mouth for 9 months.

    Drug: Placebo oral capsule

Interventions

  • Nefecon 16 mg for daily administration by mouth for 9 months.

    Also known as: Budesonide modified released capsule

  • DrugPlacebo oral capsule

    Placebo capsules for daily administration by mouth for 9 months.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline

    Part A primary endpoint: The ratio of Urine Protein to Creatinine Ratio (UPCR) (based on 24-hour urine collections) at 9 months following the first dose of study drug compared to baseline. Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram

    Time frame: 9 months

  2. Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR)

    Part B Primary endpoint: Time-weighted average of estimated glomerular filtration rate (eGFR) recordings observed at each time point over 2 years. The eGFR (CKD-EPI) at 2 years (which must have been repeated to provide a second value obtained within 14 to 35 days) was the geometric mean of the 2 assessments.

    Time frame: Up to 2 years and 1 month

Secondary outcomes

  1. Part A: Ratio of eGFR at 9 Months

    Part A: Ratio of eGFR at 9 months compared to baseline calculated using the CKD-EPI formula.

    Time frame: 9 months

  2. Part A: Ratio of eGFR at 12 Months

    Part A: Ratio of eGFR at 12 months compared to baseline calculated using the CKD-EPI formula.

    Time frame: 12 months

  3. Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months

    Part A: Ratio of urine albumin to creatinine ratio (UACR) at 9 months compared to baseline.

    Time frame: 9 months

  4. Part B: Time to 30% Reduction in eGFR

    Part B: Time to 30% reduction from baseline in eGFR (CKD-EPI) confirmed by a second value. For clarity: Please note that the number of patients with a 30% reduction is presented with statistical analysis of the time to 30% reduction.

    Time frame: Over 2 years

  5. Part B: Time to Receiving Rescue Medication.

    Part B: Time from the first dose of study drug until receiving rescue medication. For clarity: Please note that the number of patients receiving rescue medication is presented with statistical analysis of the time to receiving rescue medication.

    Time frame: Over 2 years

  6. Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months

    Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug

    Time frame: 12, 18 and 24 months

  7. Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months

    Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug.

    Time frame: 12 to 24 months

  8. Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months

    Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug;

    Time frame: 12 to 24 months

  9. Part B: Proportion of Patients Without Microhematuria

    Part B: Proportion of patients without microhematuria in at least 2 of the following time points: 12, 18, and 24 months following the first dose of study drug

    Time frame: 12 to 24 months

  10. Part B: Short Form 36 (SF-36) Quality of Life Assessment at 9 Months.

    Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.

    Time frame: 9 months

  11. Part B: Short Form 36 (SF-36) Quality of Life Assessment at 24 Months.

    Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.

    Time frame: 24 months

07

Results

Posted Dec 3, 2024

Participant flow

Part A
Participant flow — Part A
MilestoneNefeconPlacebo Oral Capsule
Started182182
Completed175174
Not completed78
Part B
Participant flow — Part B
MilestoneNefeconPlacebo Oral Capsule
Started175174
Completed161165
Not completed149

Outcome measures

PrimaryPart A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline

Part A primary endpoint: The ratio of Urine Protein to Creatinine Ratio (UPCR) (based on 24-hour urine collections) at 9 months following the first dose of study drug compared to baseline. Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram

Time frame:
9 months
Reported as:
Geometric least squares mean · ratio
Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline
ratioNefeconPlacebo Oral Capsule
Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline0.69 (0.61 to 0.79)0.95 (0.83 to 1.08)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · MMRM model · p = 0.0003 · Ratio of geometric ls means: 0.73 · 96% CI 0.61 to 0.88
PrimaryPart B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR)

Part B Primary endpoint: Time-weighted average of estimated glomerular filtration rate (eGFR) recordings observed at each time point over 2 years. The eGFR (CKD-EPI) at 2 years (which must have been repeated to provide a second value obtained within 14 to 35 days) was the geometric mean of the 2 assessments.

Time frame:
Up to 2 years and 1 month
Reported as:
Geometric least squares mean · mL/min/1.73m2
Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73m2NefeconPlacebo Oral Capsule
Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR)0.96 (0.93 to 0.98)0.87 (0.84 to 0.89)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · robust regression · p = <0.0001 · Ratio of geometric ls means: 1.10 · 95% CI 1.06 to 1.15
SecondaryPart A: Ratio of eGFR at 9 Months

Part A: Ratio of eGFR at 9 months compared to baseline calculated using the CKD-EPI formula.

Time frame:
9 months
Reported as:
Geometric least squares mean · mL/min/1.73m2
Part A: Ratio of eGFR at 9 Months
mL/min/1.73m2NefeconPlacebo Oral Capsule
Part A: Ratio of eGFR at 9 Months1.00 (0.96 to 1.03)0.93 (0.90 to 0.96)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · robust regression · p = 0.0014 · Ratio of geometric ls means: 1.07 · 95% CI 1.03 to 1.13
SecondaryPart A: Ratio of eGFR at 12 Months

Part A: Ratio of eGFR at 12 months compared to baseline calculated using the CKD-EPI formula.

Time frame:
12 months
Reported as:
Geometric least squares mean · mL/min/1.73m2
Part A: Ratio of eGFR at 12 Months
mL/min/1.73m2NefeconPlacebo Oral Capsule
Part A: Ratio of eGFR at 12 Months0.97 (0.93 to 1.01)0.91 (0.88 to 0.95)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · robust regression · p = 0.0106 · Ratio of geometric ls means: 1.07 · 95% CI 1.01 to 1.13
SecondaryPart A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months

Part A: Ratio of urine albumin to creatinine ratio (UACR) at 9 months compared to baseline.

Time frame:
9 months
Reported as:
Geometric least squares mean · g/gram
Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months
g/gramNefeconPlacebo Oral Capsule
Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months0.64 (0.55 to 0.75)0.93 (0.80 to 1.09)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · MMRM model · p = 0.0005 · Ratio of geometric ls means: 0.69 · 95% CI 0.55 to 0.86
SecondaryPart B: Time to 30% Reduction in eGFR

Part B: Time to 30% reduction from baseline in eGFR (CKD-EPI) confirmed by a second value. For clarity: Please note that the number of patients with a 30% reduction is presented with statistical analysis of the time to 30% reduction.

Time frame:
Over 2 years
Reported as:
Number · Participants
Part B: Time to 30% Reduction in eGFR
ParticipantsNefeconPlacebo Oral Capsule
Part B: Time to 30% Reduction in eGFR2139
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · Cox proportional hazards model · p = 0.0028 · Hazard ratio (hr): 0.45 · 95% CI 0.26 to 0.75Cox proportional hazards model with individual patient censoring weighting.
SecondaryPart B: Time to Receiving Rescue Medication.

Part B: Time from the first dose of study drug until receiving rescue medication. For clarity: Please note that the number of patients receiving rescue medication is presented with statistical analysis of the time to receiving rescue medication.

Time frame:
Over 2 years
Reported as:
Number · Participants
Part B: Time to Receiving Rescue Medication.
ParticipantsNefeconPlacebo Oral Capsule
Part B: Time to Receiving Rescue Medication.1520
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · Cox proportional hazards model · p = 0.2647 · Hazard ratio (hr): 0.68 · 95% CI 0.34 to 1.33
SecondaryPart B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months

Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug

Time frame:
12, 18 and 24 months
Reported as:
Geometric least squares mean · g/gram
Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months
g/gramNefeconPlacebo Oral Capsule
Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months0.60 (0.54 to 0.66)1.01 (0.91 to 1.12)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · MMRM model · p = <0.0001 · Ratio of geometric ls means: 0.59 · 95% CI 0.51 to 0.68
SecondaryPart B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months

Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug.

Time frame:
12 to 24 months
Reported as:
Geometric least squares mean · g/gram
Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months
g/gramNefeconPlacebo Oral Capsule
Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months0.52 (0.46 to 0.58)0.96 (0.86 to 1.08)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · MMRM model · p = <0.0001 · Ratio of geometric ls means: 0.54 · 95% CI 0.45 to 0.63
SecondaryPart B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months

Part B: Ratio of UPCR, UACR, and eGFR (CKD-EPI) compared to baseline averaged over time points between 12 and 24 months, inclusive, following the first dose of study drug;

Time frame:
12 to 24 months
Reported as:
Geometric least squares mean · mL/min/1.73m2
Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months
mL/min/1.73m2NefeconPlacebo Oral Capsule
Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months0.93 (0.90 to 0.96)0.84 (0.81 to 0.86)
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · robust regression · p = <0.0001 · Ratio of geometric ls means: 1.11 · 95% CI 1.06 to 1.16
SecondaryPart B: Proportion of Patients Without Microhematuria

Part B: Proportion of patients without microhematuria in at least 2 of the following time points: 12, 18, and 24 months following the first dose of study drug

Time frame:
12 to 24 months
Reported as:
Count of participants · Participants
Part B: Proportion of Patients Without Microhematuria
ParticipantsNefeconPlacebo Oral Capsule
Part B: Proportion of Patients Without Microhematuria9459
Statistical analysis
  • Nefecon vs Placebo Oral Capsule · Regression, Logistic · p = 0.0001 · Odds ratio (or): 2.5 · 95% CI 1.6 to 4.1
SecondaryPart B: Short Form 36 (SF-36) Quality of Life Assessment at 9 Months.

Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.

Time frame:
9 months
Reported as:
Mean · Percentage of total possible score
Part B: Short Form 36 (SF-36) Quality of Life Assessment at 9 Months.
Percentage of total possible scoreNefeconPlacebo Oral Capsule
Bodily Pain54.353 ± 9.030654.659 ± 9.2387
General Health47.058 ± 9.637348.014 ± 10.0120
Mental Component Summary49.564 ± 9.283449.760 ± 8.8974
Mental Health50.226 ± 8.953950.099 ± 8.8483
Physical Component Summary52.257 ± 7.218853.732 ± 6.5876
Physical Functioning52.722 ± 6.737054.276 ± 5.2243
Role Emotional49.574 ± 9.432250.393 ± 8.3001
Role Physical51.028 ± 8.020752.693 ± 6.6600
Social Function50.941 ± 8.360651.707 ± 7.9259
Vitality51.826 ± 10.090953.490 ± 9.3987
SecondaryPart B: Short Form 36 (SF-36) Quality of Life Assessment at 24 Months.

Part B: Short Form 36 (SF-36) quality of life assessment at 9 and 24 months. The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Higher scores indicate better health. Scores represent the percentage of total possible score achieved.

Time frame:
24 months
Reported as:
Mean · Percentage of total possible score
Part B: Short Form 36 (SF-36) Quality of Life Assessment at 24 Months.
Percentage of total possible scoreNefeconPlacebo Oral Capsule
Bodily Pain53.385 ± 9.635253.208 ± 9.9811
General Health47.038 ± 9.345047.214 ± 9.9564
Mental Component Summary51.246 ± 8.136249.743 ± 10.2184
Mental Health51.691 ± 8.210450.294 ± 10.0007
Physical Component Summary51.443 ± 7.520051.993 ± 7.1783
Physical Functioning52.665 ± 7.636453.059 ± 6.9006
Role Emotional50.322 ± 8.469049.333 ± 10.0789
Role Physical50.948 ± 7.892150.722 ± 8.8255
Social Function51.949 ± 7.967751.471 ± 8.9304
Vitality53.291 ± 8.855852.364 ± 10.0023

Adverse events

Collected over AEs were recorded from time of first dose of study treatment until 2 years after first dose (end of study). Treatment emergent AEs were those that occurred after the first dose of study drug until 14 days after the last dose, including tapering. SAEs were recorded from time of patient informed consent until end of study, i.e until 2 years and 3 months (including follow-up period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nefecon1/182 (0.5%)18/182 (9.9%)108/182 (59.3%)
Placebo Oral Capsule0/182 (0%)9/182 (4.9%)69/182 (37.9%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventNefeconPlacebo Oral Capsule
Corona virus infectionInfections and infestations2/1820/182
PneumoniaInfections and infestations2/1820/182
Acute kidney injuryRenal and urinary disorders1/1822/182
Renal impairmentRenal and urinary disorders2/1820/182
HypertensionVascular disorders2/1820/182
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/1820/182
Campylobacter colitisInfections and infestations0/1821/182
DiverticulitisInfections and infestations0/1821/182
ErysipelasInfections and infestations1/1820/182
Nephrotic syndromeRenal and urinary disorders1/1820/182
Most frequent other events
Showing 10 of 15
Most frequent other events
EventNefeconPlacebo Oral Capsule
Edema peripheralGeneral disorders28/1827/182
Muscle spasmsMusculoskeletal and connective tissue disorders22/1827/182
HypertensionVascular disorders21/1826/182
AcneSkin and subcutaneous tissue disorders20/1822/182
NasopharyngitisInfections and infestations17/18219/182
HeadacheGeneral disorders19/18214/182
DyspepsiaGastrointestinal disorders13/1824/182
ArthralgiaMusculoskeletal and connective tissue disorders12/1824/182
NauseaGastrointestinal disorders8/18212/182
Upper respiratory tract infectionInfections and infestations10/18210/182

Baseline characteristics

Full analysis set - Global study

Age, Continuous
Age, Continuous(years)NefeconPlacebo Oral CapsuleTotal
Mean43.8 ± 10.7841.6 ± 10.6542.7 ± 10.76
Sex: Female, Male
Sex: Female, Male(Participants)NefeconPlacebo Oral CapsuleTotal
Female6559124
Male117123240
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NefeconPlacebo Oral CapsuleTotal
American Indian or Alaska Native000
Asian434083
Native Hawaiian or Other Pacific Islander000
Black or African American000
White138137275
More than one race000
Unknown or Not Reported156
Baseline Urine protein to creatinine ratio (UPCR)
Baseline Urine protein to creatinine ratio (UPCR)(g/gram)NefeconPlacebo Oral CapsuleTotal
Geometric mean1.300 (0.902 to 1.764)1.264 (0.877 to 1.737)1.282 (0.892 to 1.752)
Baseline Estimated glomerular filtration rate (eGFR)
Baseline Estimated glomerular filtration rate (eGFR)(ml/min/1.73 m2)NefeconPlacebo Oral CapsuleTotal
Geometric mean56.006 (45.497 to 70.972)55.565 (45.957 to 67.735)55.785 (45.929 to 69.839)
08

Study locations

142 sites
  • University of Alabama at Birmingham, 1720 2nd Ave South
    Birmingham, Alabama 35294-3412, United States
  • Univ of Arizona, 1501 N Campbell Ave
    Tucson, Arizona 85724, United States
  • Stanford University Medical Center, 777 Welch Rd
    Palo Alto, California 94304, United States
  • Los Angeles Biomedical Research Institute at HUMC, 1124 W. Carson Street
    Torrance, California 90502, United States
  • University of Colorado Health Science Center, 1200 East 19th Av.
    Aurora, Colorado 80045, United States
  • Western Nephrology and Metabolic Bone Disease, PC-Westerminster, 8410 Decatur St.
    Westminster, Colorado 80031, United States
  • Yale University School of Medicine, 330 Cedar Street
    New Haven, Connecticut 06520, United States
  • Washington Nephrology Associates-Washington DC, 730 24th Street NW
    Washington, District of Columbia 20037, United States
  • University of Florida-Gainesville
    Gainesville, Florida 32610, United States
  • Omega Research Maitland, 7912 Forest City Rd.
    Orlando, Florida 32810, United States
  • Omega Research Maitland
    Orlando, Florida 32810, United States
  • Northwestern University the Feinberg School of Medicine, 633 North St. Clair
    Chicago, Illinois 60611, United States
  • Northshore University Health System, 2650 Ridge Av.
    Evanston, Illinois 60201, United States
  • University of Kentucky Medical Center, 800 Rose St, Pavillion H 3rd floor
    Lexington, Kentucky 40536, United States
  • University of Louisville-Nephrology
    Louisville, Kentucky 40202, United States
  • Kidney Care and Transplant Services of New England, PC, 354 Birnie Av.
    Springfield, Massachusetts 01107, United States
  • University of Minnesota, 717 Delaware St. SE
    Minneapolis, Minnesota 55414, United States
  • Clinical Research Consultants, LLC, 3930 Washington St
    Kansas City, Missouri 64111, United States
  • Queens Hospital Centre
    Jamaica, New York 11432, United States
  • Icahn School of Medicine at Mount Sinai-James J. Peters VA Medical Center, One Gustave L. Levy Place
    New York, New York 10029, United States
  • Columbia Univ Medical Center, Div of Nephrology, 51 Audubon Av
    New York, New York 10032, United States
  • Mountain Kidney & Hypertension Assoc, 10 McDowell St
    Asheville, North Carolina 28801, United States
  • University of North Carolina at Chapel Hill, Clinical & Translational Research Centre
    Chapel Hill, North Carolina 27599, United States
  • Southeastern Nephrology-Whiteville, 800 Jefferson St
    Whiteville, North Carolina 28472, United States
  • Southeastern Nephrology Associates-Wilmington, 1302 Medical Center Drive
    Wilmington, North Carolina 28401, United States
  • Cleveland Clinic, Glickman Urological & Kidney Institute, 9500 Euclid Av.
    Cleveland, Ohio 44195, United States
  • The Ohio State University (OSU), Wexner Medical Center, 410 West 10th Av.
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University, 3181 SW Sam Jackson Park Rd
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University, 211 S. 9th Street
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny General Hospital, 4800 Friendship Av.
    Pittsburgh, Pennsylvania 15224, United States
  • Nephrology Associates, P.C., 28 White Bridge Rd
    Nashville, Tennessee 37205, United States
  • Renal Disease Research Institute, 1250 Eighth Av. #135
    Fort Worth, Texas 76104, United States
  • University of Vermont
    Burlington, Vermont 05401, United States
  • Hospital Britanico de Buenos Aires, Pedriel 74
    Capital federal, C1280AEB, Argentina
  • Clinica Priv Velez Sarsfield
    Córdoba, 5000, Argentina
  • Hospital Privado-Centro Medico de Cordoba, Naciones Unidas 346, Nefrologia piso 1
    Córdoba, 5016, Argentina
  • Sanatorio Allende, Hipolito Yrigoyen 384, 2 Piso
    Córdoba, X5000JHQ, Argentina
  • Hospital Universitario Austral, Unidad de Investigacion Clinica, Av. J.D. Peron 1500, piso 4
    Pilar, B16290DT, Argentina
  • Clinico de Nefrologia, Urologia Y Enfermedades Cardiovasculares, Av. Gdor Freyre 3074
    Santa Fe, 3000, Argentina
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Adelaide Hospital, Port Rd.
    Adelaide, 5000, Australia
  • Box Hill Hospital, Dept of Renal Medicine, Arnold Str 5
    Box Hill, 3128, Australia
  • Austin Health, Dept of Nephrology, 145 Studley Rd.
    Heidelberg, 3084, Australia
  • Melbourne Health, Royal Melbourne Hospital, Dept of Nephrology,Grattan Str.
    Parkville, 3052, Australia
  • Prince of Wales Hospital, Nephrology Dept, Parkes 3 West
    Randwick, 2031, Australia
  • Western Health, Western Hospital-Sunshine Hospital, 176 Furlong Rd, Level 3, WHCRE Building
    St Albans, 3021, Australia
  • Westmead Hospital, Dept of Renal Medicine, Hawkesbury Rd.
    Westmead, 2145, Australia
  • Metro South Hospital and Health Service via Princess Alexandra Hospital, Dept of Nephrology, 199 Ipswich Rd.
    Woolloongabba, 4102, Australia
  • Brest Regional Hospital, 7 Meditsinskaya str.
    Brest, 224027, Belarus
  • Gomel Regional Clinical Hospital, 5 Brat'ev Lizukovyh str.
    Gomel, 246029, Belarus
  • Grodno Regional Clinical Hospital, 52 Bulvar Leninskogo Komsomola
    Grodno, 230030, Belarus
  • 4-th N.E. Savchenko City Clinical Hospital, 110, R. Luxemburg str.
    Minsk, 220036, Belarus
  • University Hospital Erasmus (Brussels), Recherche Clinique Nephrologie Transplantation, Route de Lennik 808
    Brussels, 1070, Belgium
  • Cliniques Universitaires Saint-Luc, Nephrology Dept, Av. Hippocrate 10
    Brussel, 1200, Belgium
  • University Hospital Gent, Dept of Medical Nephrology, Corneel Heymanslaan 10
    Gent, 9000, Belgium
  • Centre Hospitalier Universitaire de Liege, Nephrology Dept. Domaine Universitaire de Sart-Tilman
    Liège, 4000, Belgium
  • AZ Delta, Wilgenstraat 2
    Roeselare, 8800, Belgium
  • Royal Inland Hospital, Kidney Clinic, 7 South, 311 Columbia Street
    Kamloops, British Columbia V2C 2T1, Canada
  • Interior Health-Kelowna General Hosp (IH KGH), 2268 Pandosy Str.
    Kelowna, British Columbia V1Y 1T2, Canada
  • Vancouver Coastal Health Authority, Gordon and Leslie Diamond Health Care Centre, 5 th floor, Diamond Building
    Vancouver, British Columbia V5T 3A5, Canada
  • Queen Elizabeth II Health Sciences Centre, 1276 South Park St
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Kingston General Hospital
    Kingston, Ontario K7L2V7, Canada
  • Hospital Maisonneuve-Rosemont, CNIB 3rd Floor, 1929 Bayview Avenue
    Toronto, Ontario M4G 3E8, Canada
  • Toronto General Hospital, University Health Network, 200 Elizabeth St, 8 N-849
    Toronto, Ontario M5G2C4, Canada
  • CISSS de la Monteregie-Centre-Hopital Charles LeMoyne, Room E-304, 3120 Taschereau Blvd
    Greenfield Park, Quebec J4V 2H1, Canada
  • CHUQ-L'Hotel Dieu de Quebec, 11 côte du Palais
    Québec City, Quebec G1R 2J6, Canada
  • Centre Hospiitalier Universitaire de Sherbrooke (CHUS), 3001, 12e Avenue Nord
    Sherbrooke, Quebec J1H 5N4, Canada
  • Fakultni nemocnice Brno, Interni gastroenterologicka klinika, Jihlavska 20
    Brno, 62500, Czechia
  • Fakultni nemocnice Hradec Kralove, Sokolska 581
    Hradec Králové, 50005, Czechia
  • Fakultni nemocnice Olomouc, I.P. Pavlova 185/6
    Olomouc, 77900, Czechia
  • Fakultni nemocnice Kralovske Vinohrady, Linterni klinika, Srobarova 1150/50
    Praha 10, 10034, Czechia
  • Vseobecna fakultni nemocnice v Praze, Klinik nefrologie, U Nemocnice 499/2
    Praha 2, 12808, Czechia
  • Helsinki University Central Hospital (HUCH), Nephrology Clinic, Meilahti Triangle Hospital
    Helsinki, 00290, Finland
  • Study Cor Oy, Hoitajantie 4
    Jyväskylä, 40620, Finland
  • Tampere University Hospital, P O Box 2000, Munuaiskeskus, Erakennus, 1. kerros
    Tampere, 33520, Finland
  • Centre Hospitalier Boulogne sur Mer, 4eme etage Batiment Administratif, Allee Jacques Monod
    Boulogne-sur-Mer, 62321, France
  • CHU Grenoble-Hopital Michallon, Service Nephrologie-Hemodialyse-Aphereses-Transplantation Renale, Boulevard de la Chantourne CS 10217
    Grenoble, 30043, France
  • Lapeyronie Hospital, Univ Hospital Montpellier, 371 Av. du Doyen Gaston Giraud
    Montpellier, 34295, France
  • Hopital Bichat-Claude Bernard, Service de Nephrologie, 46 rue Henri Huchard
    Paris, 75877, France
  • Chu St Etienne-Hopital Nord, Service de Nephrologie Dialyse Transplantation renale, Av. Albert Raimond
    Saint-Priest-en-Jarez, 42270, France
  • Centre Hospitalier de Valenciennes, Service de Nephrologie-Medecine Interne, Av. Desandrouin BP 379
    Valenciennes, 59322, France
  • Uniklinik RWTH Aachen, Medizinische Klinik II, Pauwelsstrasse 30
    Aachen, 52074, Germany
  • Universitaetsklinikum Carl Gustav Carus Dresden, Medizinische Klinik III, Nephrologie, Fetscherstr. 74
    Dresden, 01307, Germany
  • Universitaetsklinikum Erlangen, Medizinisches Klinik 4, Ulmenweg 18
    Erlangen, 91054, Germany
  • Universitaetsklinikum Heidelberg-Nephrologie, Renal Clinic, Im Neuenheimer Feld 162
    Heidelberg, 69120, Germany
  • Universitatsklinik Schleswig-Holstein-Campus Lubek, Medizinische Klinik I, Nephrologie, Ratzeburger Allee 160
    Lubeck, 23538, Germany
  • University Clinic Munich, LMU-Inner City Medical Polyclinic, Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV
    Munich, 80336, Germany
  • Universitaetsklinikum Regensburg, Abteilung für Nephrologie, Franz-Josef-Strauss Allee 11
    Regensburg, 93053, Germany
  • General Hospital of Athens-Laiko, Nephrology Clinic, 17 Agiou Thoma Street
    Athens, 11527, Greece
  • University Hospital of Heraklion, Nephrology Clinic, Diastaurosi Staurakion-Vouton
    Heraklion, 71100, Greece
  • University General Hospital of Ioannina, Nephrology Clinic, Leof. Stavros Niarchou
    Ioánnina, 45110, Greece
  • University Hospital of Larissa Medical School, Nefrology Clinic, Mezourlo
    Larissa, 41110, Greece
  • General Hospital of Nikaia Ag. Panteleimon, Nephrology Clinic, Mantouvalou 3 Str.
    Níkaia, 18454, Greece
  • University General Hospital of Patras, Rio
    Patras, 26504, Greece
  • Hippokration General Hosp of Thessaloniki, Nephrology Clinic, 49 Konstantinoupoleos Str
    Thessaloníki, 54642, Greece
  • Azienda Ospedale Policlinico di Bari
    Bari, 70124, Italy
  • ASST di Lecco, Presidio Ospedaliero Alessandro Manzoni, Via dell´Eremo 9/11
    Lecco, 23900, Italy
  • Ospedale San Carlo Borromeo, Via Pio II, 3
    Milano, 20153, Italy
  • Istituti Clinici Scientifici Maugeri Spa-Societa Benefit, Div. di Nephrologia ed Emodialist, Via S. Maugeri 10
    Pavia, 27100, Italy

Showing the first 100 of 142 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sorensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28. PubMed 28363480 ↗
  • Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. PubMed 36270561 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Jul 2023, 58 months.

Results were first posted in Dec 2024, 1 year 4 months after primary completion.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 58 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2018
First posted
Aug 23, 2018
StartActual
Sep 5, 2018
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Results first posted
Dec 3, 2024
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03643965
Lead sponsor
Calliditas Therapeutics AB
Responsible party
Sponsor
First posted
Aug 23, 2018
Start date
Sep 5, 2018
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Results posted
Dec 3, 2024
Last update
Dec 3, 2024

Study contacts

Krassimir Mitchev, MD
study director · Calliditas AB

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion